<DOC>
	<DOCNO>NCT00919854</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( body medication ) , safety antiviral activity support dose recommendation body weight darunavir low-dose ritonavir ( DRV/rtv ) , combination antiretroviral drug ( ARVs ) , treatment-experienced Human immunodeficiency virus 1 ( HIV 1 ) infect child .</brief_summary>
	<brief_title>A Safety Study Evaluate Antiviral Activity Darunavir Combination With Ritonavir HIV 1 Infected Children</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , study evaluate pharmacokinetics , safety antiviral activity . Approximately 24 HIV-1 infected child enrol study . The study consist 4-week screening period , 48-week treatment period , 4-week follow-up period . Participants receive DRV/rtv accord body weight . Safety evaluation include assessment adverse event , laboratory test , physical Examination , neurologic examination , vital sign , electrocardiogram . The total duration study 56 week .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Participants document HIV 1 infection ( local standard diagnostic method , HIV PCRDNA , ELISA western blot ( WB ) test HIV antibody , etc . ) Body weight 10 kg less 20 kg screen Participants currently stable ART ( anti retroviral therapy ) least 12 week , need change ARV regimen currently fail , viral load great 1000 copies/mL Screening genotype resistance test result show less 3 DRV resistanceassociated mutation Parents legal representative willing able give consent Participants presence currently active condition include listing WHO ( World Health Organisation ) Clinical Stage 4 participant presence nonHIV encephalopathy Administration ARV ( antiretroviral ) nonARV investigational medication investigational vaccine within 30 day prior screen , except medication dose recommendation child available Life expectancy le 6 month , accord judgment investigator Coenrollment clinical and/or cohort trial without write permission Sponsor Participants active clinically significant disease ( eg , tuberculosis [ TB ] , cardiac dysfunction , pancreatitis , acute viral infection ) finding screen medical history physical examination , investigator 's opinion , would compromise subject 's safety outcome study</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Human immunodeficiency virus 1</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Darunavir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Norvir</keyword>
</DOC>